3/12
08:48 am
asnd
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
Low
Report
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
3/5
05:03 pm
asnd
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
Low
Report
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
3/4
10:52 pm
asnd
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
3/4
10:14 pm
asnd
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
Low
Report
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
3/4
09:09 pm
asnd
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.
Low
Report
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.
3/4
06:06 am
asnd
Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
Low
Report
Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
3/2
09:02 pm
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
3/2
05:00 pm
asnd
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]
Low
Report
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]
3/2
04:22 pm
asnd
Ascendis wins FDA approval of dwarfism drug [Yahoo! Finance]
Low
Report
Ascendis wins FDA approval of dwarfism drug [Yahoo! Finance]
3/2
01:05 pm
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wolfe Research.
Low
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wolfe Research.
3/2
01:05 pm
asnd
Ascendis Pharma A/S (ASND) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Low
Report
Ascendis Pharma A/S (ASND) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
3/2
11:04 am
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Evercore Inc.
Medium
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Evercore Inc.
3/2
08:43 am
asnd
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
3/2
07:01 am
asnd
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
Medium
Report
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
2/27
06:15 pm
asnd
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older [Yahoo! Finance]
Medium
Report
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older [Yahoo! Finance]
2/27
05:57 pm
asnd
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Medium
Report
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
2/24
09:32 pm
asnd
Assessing Ascendis Pharma (ASND) Valuation After Strong 1 Year Return And Growing Growth Expectations [Yahoo! Finance]
Low
Report
Assessing Ascendis Pharma (ASND) Valuation After Strong 1 Year Return And Growing Growth Expectations [Yahoo! Finance]
2/23
05:31 pm
asnd
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Low
Report
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
2/23
05:31 pm
asnd
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Low
Report
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
2/21
05:42 am
asnd
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth [Yahoo! Finance]
Medium
Report
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth [Yahoo! Finance]
2/13
08:32 am
asnd
The Boston Globe to Host Rare Disease Summit
Low
Report
The Boston Globe to Host Rare Disease Summit
2/12
10:06 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $325.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $325.00 price target on by analysts at Stifel Nicolaus.
2/12
10:00 am
asnd
BioNJ Elects Board Officers and Trustees
Low
Report
BioNJ Elects Board Officers and Trustees
2/12
09:46 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Wedbush from $240.00 to $273.00. They now have an "outperform" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Wedbush from $240.00 to $273.00. They now have an "outperform" rating on the stock.
2/12
09:02 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..